Invivyd Inc. has announced plans to engage with the U.S. Food and Drug Administration (FDA) on an expedited pathway to develop next-generation COVID-19 prevention and treatment options. This initiative comes as the FDA acknowledges uncertainties in the efficacy of current COVID-19 vaccine boosters and aligns with Invivyd's Citizen Petition requests. The company aims to advance its monoclonal antibody therapies, including the investigational mAb VYD2311, to provide scalable and high-quality protection against modern immune-evasive SARS-CoV-2 viruses. Invivyd anticipates a clinical update on VYD2311 this quarter, marking a significant step in addressing the ongoing challenges posed by COVID-19, especially for high-risk populations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.